PL2099442T3 - Sposób stosowania inhibitorów deacetylazy histonów i monitoringu biomarkerów w terapii skojarzonej - Google Patents
Sposób stosowania inhibitorów deacetylazy histonów i monitoringu biomarkerów w terapii skojarzonejInfo
- Publication number
- PL2099442T3 PL2099442T3 PL07869059T PL07869059T PL2099442T3 PL 2099442 T3 PL2099442 T3 PL 2099442T3 PL 07869059 T PL07869059 T PL 07869059T PL 07869059 T PL07869059 T PL 07869059T PL 2099442 T3 PL2099442 T3 PL 2099442T3
- Authority
- PL
- Poland
- Prior art keywords
- combination therapy
- histone deacetylase
- deacetylase inhibitors
- monitoring biomarkers
- biomarkers
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87190006P | 2006-12-26 | 2006-12-26 | |
EP07869059.1A EP2099442B1 (en) | 2006-12-26 | 2007-12-07 | Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy |
PCT/US2007/086874 WO2008082856A1 (en) | 2006-12-26 | 2007-12-07 | Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2099442T3 true PL2099442T3 (pl) | 2015-04-30 |
Family
ID=39588962
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL07869059T PL2099442T3 (pl) | 2006-12-26 | 2007-12-07 | Sposób stosowania inhibitorów deacetylazy histonów i monitoringu biomarkerów w terapii skojarzonej |
Country Status (17)
Country | Link |
---|---|
US (1) | US9408816B2 (pl) |
EP (2) | EP2099442B1 (pl) |
JP (2) | JP2010514777A (pl) |
KR (2) | KR20120090100A (pl) |
CN (1) | CN101674820B (pl) |
AU (1) | AU2007340129B2 (pl) |
CA (1) | CA2674084C (pl) |
CY (1) | CY1116019T1 (pl) |
DK (1) | DK2099442T3 (pl) |
ES (1) | ES2529147T3 (pl) |
NZ (1) | NZ578428A (pl) |
PL (1) | PL2099442T3 (pl) |
PT (1) | PT2099442E (pl) |
RU (2) | RU2446796C2 (pl) |
SI (1) | SI2099442T1 (pl) |
WO (1) | WO2008082856A1 (pl) |
ZA (1) | ZA200905060B (pl) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0409227C1 (pt) | 2003-04-07 | 2021-05-25 | Axys Pharm Inc | composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i) |
PT2099442E (pt) | 2006-12-26 | 2015-02-10 | Pharmacyclics Inc | Métodos de utilização de inibidores de histona desacetilase e monitorização de biomarcadores em terapia de combinação |
EP2156370B1 (en) | 2007-05-14 | 2011-10-12 | Historx, Inc. | Compartment segregation by pixel characterization using image data clustering |
ES2599902T3 (es) * | 2007-06-15 | 2017-02-06 | Novartis Ag | Sistema y método de microscopio para obtener datos de muestra normalizados |
CA2604317C (en) | 2007-08-06 | 2017-02-28 | Historx, Inc. | Methods and system for validating sample images for quantitative immunoassays |
CA2596204C (en) * | 2007-08-07 | 2019-02-26 | Historx, Inc. | Method and system for determining an optimal dilution of a reagent |
US7978258B2 (en) * | 2007-08-31 | 2011-07-12 | Historx, Inc. | Automatic exposure time selection for imaging tissue |
JP2011524743A (ja) * | 2008-06-02 | 2011-09-08 | アンスティテュ・グスターブ・ルシ | ナチュラルキラーp30(NKp30)機能障害及びその生物学的用途 |
US9240043B2 (en) | 2008-09-16 | 2016-01-19 | Novartis Ag | Reproducible quantification of biomarker expression |
WO2010114805A1 (en) * | 2009-03-31 | 2010-10-07 | The Trustees Of The University Of Pennsylvania | Methods of treating cancer with phenformin |
US8603521B2 (en) | 2009-04-17 | 2013-12-10 | Pharmacyclics, Inc. | Formulations of histone deacetylase inhibitor and uses thereof |
WO2011056542A1 (en) * | 2009-10-26 | 2011-05-12 | Ramot At Tel-Aviv University Ltd. | Cancer therapy with combinations of fts with hdac inhibitors |
EP2322658A1 (en) | 2009-11-13 | 2011-05-18 | Centre National de la Recherche Scientifique (CNRS) | Signature for the diagnosis of breast cancer aggressiveness and genetic instability |
WO2011103563A1 (en) * | 2010-02-22 | 2011-08-25 | Arno Therapeutics, Inc | Methods and compositions for inhibiting and preventing the growth of malignant mast cells |
WO2011153514A2 (en) | 2010-06-03 | 2011-12-08 | Pharmacyclics, Inc. | The use of inhibitors of bruton's tyrosine kinase (btk) |
CN103827314A (zh) | 2011-05-18 | 2014-05-28 | 国家科学研究中心 | 用于诊断癌侵袭性和遗传不稳定性的标记 |
RU2644635C2 (ru) * | 2011-07-07 | 2018-02-13 | Рисёрч Кансер Инститьют Оф Америка | Системы, способы и составы для лечения рака |
US8933078B2 (en) | 2011-07-14 | 2015-01-13 | Research Cancer Institute Of America | Method of treating cancer with combinations of histone deacetylase inhibitors (HDAC1) substances |
SG2014014419A (en) * | 2011-09-13 | 2014-07-30 | Pharmacyclics Inc | Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof |
WO2013102680A1 (en) | 2012-01-05 | 2013-07-11 | Centre National De La Recherche Scientifique (Cnrs) | Signature for the diagnosis of lung cancer aggressiveness and genetic instability |
WO2013153532A1 (en) | 2012-04-12 | 2013-10-17 | University Of Saskatchewan | Phthalocyanine compounds useful as reca inhibitors and methods of using same |
JP6575950B2 (ja) | 2012-07-24 | 2019-09-18 | ファーマサイクリックス エルエルシー | Bruton型チロシンキナーゼ(Btk)阻害剤に対する耐性を伴う変異 |
CN103191412B (zh) * | 2013-04-01 | 2019-08-02 | 北京师范大学 | Pa200和乙酰化介导核心组蛋白通过蛋白酶体降解 |
CN103324846A (zh) * | 2013-06-13 | 2013-09-25 | 浙江加州国际纳米技术研究院绍兴分院 | 结直肠癌症治疗预后生物标记物的筛选方法 |
CN103310105A (zh) * | 2013-06-13 | 2013-09-18 | 浙江加州国际纳米技术研究院绍兴分院 | 筛选非小细胞肺癌治疗疗效生物标记物的方法 |
JP6800750B2 (ja) | 2013-08-02 | 2020-12-16 | ファーマサイクリックス エルエルシー | 固形腫瘍の処置方法 |
US9885086B2 (en) | 2014-03-20 | 2018-02-06 | Pharmacyclics Llc | Phospholipase C gamma 2 and resistance associated mutations |
RU2593342C1 (ru) * | 2015-03-26 | 2016-08-10 | Федеральное государственное бюджетное научное учреждение "Томский научно-исследовательский институт онкологии" (Томский НИИ онкологии) | Способ комбинированного лечения немелкоклеточного рака легкого 1в-111 стадии с персонификацией адъювантной химиотерапии |
US10973819B2 (en) | 2016-03-02 | 2021-04-13 | The University Of Chicago | Small molecules inhibitors of RAD51 |
KR20180126085A (ko) * | 2016-05-05 | 2018-11-26 | 난토믹스, 엘엘씨 | 체크포인트 부전 및 그 방법(checkpoint failure and methods therefor) |
MX2018014366A (es) | 2016-05-27 | 2019-04-11 | Synthex Inc | Interfaces de proteina. |
US11890292B2 (en) | 2017-02-27 | 2024-02-06 | Research Cancer Institute Of America | Compositions, methods, systems and/or kits for preventing and/or treating neoplasms |
US11369585B2 (en) | 2017-03-17 | 2022-06-28 | Research Cancer Institute Of America | Compositions, methods, systems and/or kits for preventing and/or treating neoplasms |
ES2925218T3 (es) | 2017-09-11 | 2022-10-14 | Cyteir Therapeutics Inc | Inhibidores de RAD51 |
GB2584210B (en) | 2017-11-22 | 2022-03-16 | Synthex Inc | Peptides for inhibiting RAD51 |
KR102236356B1 (ko) * | 2017-11-24 | 2021-04-05 | 주식회사 종근당 | 루푸스의 예방 또는 치료를 위한 조성물 |
KR20190118251A (ko) * | 2018-04-10 | 2019-10-18 | 주식회사 종근당 | 건성안의 예방 또는 치료를 위한 조성물 |
CN109490543B (zh) * | 2018-11-26 | 2021-08-31 | 复旦大学附属金山医院 | 一种预测胃肠间质瘤耐药性的试剂盒及其应用 |
GB201918413D0 (en) * | 2019-12-13 | 2020-01-29 | Z Factor Ltd | Compounds and their use for the treatment of alpha1-antitrypsin deficiency |
CN112485233B (zh) * | 2020-11-03 | 2022-08-26 | 山东师范大学 | 一种检测去乙酰化酶用纳米传感器及其检测方法和应用 |
CN116196314B (zh) * | 2023-05-04 | 2023-08-15 | 广州市妇女儿童医疗中心 | Ri-1或其盐在制备防治胃肠道疾病的药物中的应用 |
Family Cites Families (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3126375A (en) | 1964-03-24 | Chioacyl | ||
US2789118A (en) | 1956-03-30 | 1957-04-16 | American Cyanamid Co | 16-alpha oxy-belta1, 4-pregnadienes |
US2990401A (en) | 1958-06-18 | 1961-06-27 | American Cyanamid Co | 11-substituted 16alpha, 17alpha-substituted methylenedioxy steroids |
US3048581A (en) | 1960-04-25 | 1962-08-07 | Olin Mathieson | Acetals and ketals of 16, 17-dihydroxy steroids |
US3749712A (en) | 1970-09-25 | 1973-07-31 | Sigma Tau Ind Farmaceuti | Triamcinolone acetonide esters and process for their preparation |
BE794063A (fr) | 1972-01-17 | 1973-07-16 | Henkel & Cie Gmbh | Anti-inflammatoires pour compositions cosmetiques |
US3996359A (en) | 1972-05-19 | 1976-12-07 | Ab Bofors | Novel stereoisomeric component A of stereoisomeric mixtures of 2'-unsymmetrical 16,17-methylenedioxy steroid 21-acylates, compositions thereof, and method of treating therewith |
SE378110B (pl) | 1972-05-19 | 1975-08-18 | Bofors Ab | |
SE378109B (pl) | 1972-05-19 | 1975-08-18 | Bofors Ab | |
US3775656A (en) * | 1972-05-22 | 1973-11-27 | Aviat Inc | Platform stabilization system |
CH581818A5 (pl) * | 1973-02-27 | 1976-11-15 | Cierva Juan J De | |
EP0084236A3 (en) | 1981-12-22 | 1983-08-03 | Fbc Limited | Fungicidal heterocyclic compounds and compositions containing them |
US4498038A (en) * | 1983-02-15 | 1985-02-05 | Malueg Richard M | Stabilization system for soft-mounted platform |
GB8518301D0 (en) | 1985-07-19 | 1985-08-29 | Fujisawa Pharmaceutical Co | Hydrodynamically explosive systems |
EP0230654B1 (en) | 1985-12-28 | 1992-03-18 | Sumitomo Pharmaceuticals Company, Limited | Sustained pulsewise release pharmaceutical preparation |
US4885314A (en) | 1987-06-29 | 1989-12-05 | Merck & Co., Inc. | Novel HMG-CoA reductase inhibitors |
US4782084A (en) | 1987-06-29 | 1988-11-01 | Merck & Co., Inc. | HMG-COA reductase inhibitors |
DE3889545T2 (de) * | 1987-10-20 | 1994-10-13 | Otsuka Pharma Co Ltd | Phenylcarbonsäure-abkömmlinge. |
US5612059A (en) | 1988-08-30 | 1997-03-18 | Pfizer Inc. | Use of asymmetric membranes in delivery devices |
JPH03215470A (ja) | 1990-01-22 | 1991-09-20 | Suntory Ltd | プロピオン酸アミド誘導体,その製造法及びそれを有効成分として含有する除草剤 |
US5017381A (en) | 1990-05-02 | 1991-05-21 | Alza Corporation | Multi-unit pulsatile delivery system |
DE4124345A1 (de) * | 1991-07-23 | 1993-01-28 | Gruenenthal Gmbh | Substituierte 3,4-dihydronaphthaline, diese verbindungen enthaltende arzneimittel und verfahren zur herstellung dieser verbindungen und arzneimittel |
US5229135A (en) | 1991-11-22 | 1993-07-20 | Prographarm Laboratories | Sustained release diltiazem formulation |
US5260068A (en) | 1992-05-04 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Multiparticulate pulsatile drug delivery system |
US5260069A (en) | 1992-11-27 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Pulsatile particles drug delivery system |
DE4327365A1 (de) | 1993-08-14 | 1995-02-16 | Boehringer Mannheim Gmbh | Verwendung von Phenolen und Phenolderivaten als Arzneimittel mit fibrinogensenkender Wirkung |
US5448938A (en) * | 1993-10-18 | 1995-09-12 | Guardian Technologies International, Inc. | Removable ballistic resistant armor seat cover and floor mat |
US5567441A (en) | 1995-03-24 | 1996-10-22 | Andrx Pharmaceuticals Inc. | Diltiazem controlled release formulation |
US5798119A (en) | 1995-06-13 | 1998-08-25 | S. C. Johnson & Son, Inc. | Osmotic-delivery devices having vapor-permeable coatings |
US5837284A (en) | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
US5958957A (en) * | 1996-04-19 | 1999-09-28 | Novo Nordisk A/S | Modulators of molecules with phosphotyrosine recognition units |
ZA98376B (en) | 1997-01-23 | 1998-07-23 | Hoffmann La Roche | Sulfamide-metalloprotease inhibitors |
US5840329A (en) | 1997-05-15 | 1998-11-24 | Bioadvances Llc | Pulsatile drug delivery system |
KR100247563B1 (ko) | 1997-07-16 | 2000-04-01 | 박영구 | 키랄3,4-에폭시부티르산및이의염의제조방법 |
AU766219B2 (en) | 1998-02-02 | 2003-10-09 | 1149336 Ontario Inc. | Method of regulating glucose metabolism, and reagents related thereto |
JP2002506075A (ja) | 1998-03-09 | 2002-02-26 | フォンダテッヒ・ベネルクス・ナムローゼ・フェンノートシャップ | セリンペプチダーゼ調節剤 |
DE19823831A1 (de) | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen |
DE19828113A1 (de) | 1998-06-24 | 2000-01-05 | Probiodrug Ges Fuer Arzneim | Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV |
DE19828114A1 (de) | 1998-06-24 | 2000-01-27 | Probiodrug Ges Fuer Arzneim | Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV |
US6211197B1 (en) | 1998-10-07 | 2001-04-03 | Merck Frosst Canada & Co. | Prostaglandin receptor ligands |
GB9904387D0 (en) | 1999-02-25 | 1999-04-21 | Pharmacia & Upjohn Spa | Antitumour synergistic composition |
EP1191861A4 (en) * | 1999-05-28 | 2006-12-06 | David E Grober | AUTONOMOUS, SELF-LEVELING AND SELF-CORRECTIVE STABILIZING PLATFORM |
US6718130B2 (en) * | 1999-05-28 | 2004-04-06 | David E. Grober | Stabilized camera and marker buoy for media coverage of aquatic events |
JP2003506100A (ja) * | 1999-08-10 | 2003-02-18 | パンジーン・コーポレイション | Rad51関連分子および方法を用いる癌治療および診断 |
WO2001014331A2 (en) | 1999-08-24 | 2001-03-01 | Regents Of The University Of California | Non-quinoline inhibitors of malaria parasites |
IL148718A0 (en) * | 1999-09-17 | 2002-09-12 | Abbott Gmbh & Co Kg | Pyrazolopyrimidines as therapeutic agents |
US6921763B2 (en) * | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
DK1233958T3 (da) | 1999-11-23 | 2011-10-17 | Methylgene Inc | Hæmmere af histondeacetylase |
GB0023983D0 (en) * | 2000-09-29 | 2000-11-15 | Prolifix Ltd | Therapeutic compounds |
WO2002030879A2 (en) * | 2000-09-29 | 2002-04-18 | Prolifix Limited | Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors |
ES2318649T3 (es) * | 2000-10-20 | 2009-05-01 | EISAI R&D MANAGEMENT CO., LTD. | Procedimiento de preparacion de derivados de 4-fenoxi quinolinas. |
WO2002053775A2 (en) | 2000-12-28 | 2002-07-11 | Epidauros Biotechnologie Ag | Identification of genetic determinants of polymorphic cyp3a5 expression |
MXPA01013172A (es) * | 2001-02-14 | 2002-08-21 | Warner Lambert Co | Inhibidores sulfonamida de metaloproteinasa de matriz. |
MXPA03008560A (es) * | 2001-03-22 | 2004-06-30 | Abbot Gmbh & Co Kg | Pirazolopirimidinas como agentes terapeuticos. |
WO2002083139A1 (en) | 2001-04-10 | 2002-10-24 | Merck & Co., Inc. | Inhibitors of akt activity |
WO2002083140A1 (en) | 2001-04-10 | 2002-10-24 | Merck & Co., Inc. | Inhibitors of akt activity |
WO2002083675A2 (en) | 2001-04-10 | 2002-10-24 | Merck Sharp & Dohme Limited | Inhibitors of akt activity |
WO2002083138A1 (en) | 2001-04-10 | 2002-10-24 | Merck & Co., Inc. | Inhibitors of akt activity |
PL206069B1 (pl) * | 2001-06-28 | 2010-06-30 | Ucb Farchim Sa | Tabletka dwuwarstwowa zawierająca cetyryzynę i pseudoefedrynę |
US7247426B2 (en) * | 2001-08-02 | 2007-07-24 | Agilent Technologies, Inc. | Classifying cancers |
ITMI20011733A1 (it) * | 2001-08-07 | 2003-02-07 | Italfarmaco Spa | Derivati dell'acido idrossamico inibitori degli enzimi istone deacetilasi, quali nuovi farmaci antiinfiammatori inibenti la sintesi di citoc |
RU2298414C2 (ru) | 2001-08-21 | 2007-05-10 | Астеллас Фарма Инк. | Медицинское применение ингибитора гистоновой дезацетилазы и способ оценки его противоопухолевого действия |
US20030166026A1 (en) * | 2002-01-09 | 2003-09-04 | Lynx Therapeutics, Inc. | Identification of specific biomarkers for breast cancer cells |
EP1472379A1 (en) | 2002-02-04 | 2004-11-03 | Epidauros Biotechnologie AG | Polymorphisms in the human gene for tpmt and their use in diagnostic and therapeutic applications |
WO2003070691A1 (fr) | 2002-02-21 | 2003-08-28 | Osaka Industrial Promotion Organization | Derive de n-hydroxycarboxamide |
US20040132825A1 (en) | 2002-03-04 | 2004-07-08 | Bacopoulos Nicholas G. | Methods of treating cancer with HDAC inhibitors |
JP4394960B2 (ja) | 2002-04-08 | 2010-01-06 | メルク エンド カムパニー インコーポレーテッド | Akt活性阻害薬 |
WO2003086404A1 (en) | 2002-04-08 | 2003-10-23 | Merck & Co., Inc. | Fused quinoxaline derivatives as inhibitors of akt activity |
AU2003226250B2 (en) | 2002-04-08 | 2007-08-16 | Merck Sharp & Dohme Corp. | Inhibitors of Akt activity |
US20050130977A1 (en) | 2002-04-08 | 2005-06-16 | Lindsley Craig W. | Inhibitors of akt activity |
KR20050034732A (ko) | 2002-08-02 | 2005-04-14 | 아젠터 디스커버리 리미티드 | 히스톤 디아세틸라제 억제제로서의 치환된티에닐-히드록사믹산 |
EP1400806A1 (en) | 2002-09-18 | 2004-03-24 | G2M Cancer Drugs AG | The use of molecular markers for the preclinical and clinical profiling of inhibitors of enzymes having histone deacetylase activity |
US6769347B1 (en) * | 2002-11-26 | 2004-08-03 | Recon/Optical, Inc. | Dual elevation weapon station and method of use |
JPWO2004074478A1 (ja) | 2003-02-19 | 2006-06-01 | アステラス製薬株式会社 | ヒストンデアセチラーゼ阻害剤の抗腫瘍効果の予測方法 |
BRPI0409227C1 (pt) * | 2003-04-07 | 2021-05-25 | Axys Pharm Inc | composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i) |
CN1768031A (zh) * | 2003-04-07 | 2006-05-03 | Axys药物公司 | 作为治疗剂的异羟肟酸酯 |
PE20050206A1 (es) | 2003-05-26 | 2005-03-26 | Schering Ag | Composicion farmaceutica que contiene un inhibidor de histona deacetilasa |
GB0317466D0 (en) * | 2003-07-25 | 2003-08-27 | Univ Sheffield | Use |
EP2263694B1 (en) | 2003-09-25 | 2013-06-12 | Astellas Pharma Inc. | Antitumor agent comprising the histone deacetylase inhibitor FK228 and the topoisomerase II inhibitor doxorubicin |
EP1694866A4 (en) | 2003-12-12 | 2007-12-26 | Bayer Pharmaceuticals Corp | GENE EXPRESSION PROFILES AND METHODS OF USE |
WO2005097770A1 (en) | 2004-04-07 | 2005-10-20 | Pharmacyclics, Inc. | Novel hydroxamates as therapeutic agents |
SI1591109T1 (sl) | 2004-04-30 | 2008-10-31 | Topotarget Germany Ag | Formulacija, ki obsega inhibitor histon-deacetilaze in izkazuje dvofazno sproščanje |
CA2569277A1 (en) | 2004-06-04 | 2005-12-15 | Pfizer Products Inc. | Method for treating abnormal cell growth |
RU2271824C1 (ru) * | 2004-08-18 | 2006-03-20 | Ростовский научно-исследовательский онкологический институт МЗ РФ | Способ лечения рака легкого |
WO2006042035A2 (en) * | 2004-10-07 | 2006-04-20 | Pharmacyclics, Inc. | Method of monitoring anti-tumor activity of an hdac inhibitor |
WO2006101454A1 (en) * | 2005-03-21 | 2006-09-28 | S*Bio Pte Ltd | Benzothiophene derivatives: preparation and pharmaceutical applications |
PT2099442E (pt) | 2006-12-26 | 2015-02-10 | Pharmacyclics Inc | Métodos de utilização de inibidores de histona desacetilase e monitorização de biomarcadores em terapia de combinação |
CA2677000A1 (en) | 2007-01-30 | 2008-08-07 | Pharmacyclics, Inc. | Methods for determining cancer resistance to histone deacetylase inhibitors |
EP2060565A1 (en) | 2007-11-16 | 2009-05-20 | 4Sc Ag | Novel bifunctional compounds which inhibit protein kinases and histone deacetylases |
EP2110377A1 (en) | 2008-04-15 | 2009-10-21 | DAC S.r.l. | Spirocyclic derivatives as histone deacetylase inhibitors |
US8603521B2 (en) | 2009-04-17 | 2013-12-10 | Pharmacyclics, Inc. | Formulations of histone deacetylase inhibitor and uses thereof |
UY34295A (es) * | 2011-09-08 | 2013-04-30 | Servier Lab | Nuevo esquema de administración de la n-hidroxi -4- {2-[3- (n,ndimetilaminometil)benzofuran -2- ilcarbonilamino]etoxi}benzamida |
SG2014014419A (en) | 2011-09-13 | 2014-07-30 | Pharmacyclics Inc | Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof |
US10078105B2 (en) | 2015-09-23 | 2018-09-18 | Abb Schweiz Ag | Electrical system with arc fault detection |
-
2007
- 2007-12-07 PT PT78690591T patent/PT2099442E/pt unknown
- 2007-12-07 ES ES07869059.1T patent/ES2529147T3/es active Active
- 2007-12-07 US US11/952,985 patent/US9408816B2/en active Active
- 2007-12-07 CA CA2674084A patent/CA2674084C/en not_active Expired - Fee Related
- 2007-12-07 CN CN2007800517726A patent/CN101674820B/zh not_active Expired - Fee Related
- 2007-12-07 DK DK07869059.1T patent/DK2099442T3/en active
- 2007-12-07 KR KR1020127017261A patent/KR20120090100A/ko not_active Application Discontinuation
- 2007-12-07 RU RU2009126655/15A patent/RU2446796C2/ru not_active IP Right Cessation
- 2007-12-07 AU AU2007340129A patent/AU2007340129B2/en not_active Ceased
- 2007-12-07 PL PL07869059T patent/PL2099442T3/pl unknown
- 2007-12-07 EP EP07869059.1A patent/EP2099442B1/en not_active Not-in-force
- 2007-12-07 KR KR1020097015579A patent/KR20090101362A/ko active Application Filing
- 2007-12-07 EP EP13153757.3A patent/EP2626067A1/en not_active Withdrawn
- 2007-12-07 SI SI200731590T patent/SI2099442T1/sl unknown
- 2007-12-07 JP JP2009544149A patent/JP2010514777A/ja active Pending
- 2007-12-07 WO PCT/US2007/086874 patent/WO2008082856A1/en active Application Filing
- 2007-12-09 NZ NZ578428A patent/NZ578428A/en not_active IP Right Cessation
-
2009
- 2009-07-20 ZA ZA200905060A patent/ZA200905060B/xx unknown
-
2011
- 2011-11-29 RU RU2011148293/15A patent/RU2011148293A/ru not_active Application Discontinuation
-
2014
- 2014-02-10 JP JP2014023335A patent/JP5827706B2/ja not_active Expired - Fee Related
-
2015
- 2015-02-02 CY CY20151100112T patent/CY1116019T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
CY1116019T1 (el) | 2017-01-25 |
JP2014139181A (ja) | 2014-07-31 |
KR20120090100A (ko) | 2012-08-16 |
US9408816B2 (en) | 2016-08-09 |
CA2674084C (en) | 2013-05-14 |
CA2674084A1 (en) | 2008-07-10 |
RU2446796C2 (ru) | 2012-04-10 |
WO2008082856A1 (en) | 2008-07-10 |
EP2099442A1 (en) | 2009-09-16 |
SI2099442T1 (sl) | 2015-03-31 |
US20080153877A1 (en) | 2008-06-26 |
EP2626067A1 (en) | 2013-08-14 |
RU2009126655A (ru) | 2011-02-10 |
JP2010514777A (ja) | 2010-05-06 |
EP2099442A4 (en) | 2010-06-16 |
KR20090101362A (ko) | 2009-09-25 |
JP5827706B2 (ja) | 2015-12-02 |
NZ578428A (en) | 2012-03-30 |
CN101674820A (zh) | 2010-03-17 |
AU2007340129B2 (en) | 2012-02-02 |
ZA200905060B (en) | 2010-07-28 |
PT2099442E (pt) | 2015-02-10 |
ES2529147T3 (es) | 2015-02-17 |
DK2099442T3 (en) | 2015-02-16 |
AU2007340129A1 (en) | 2008-07-10 |
CN101674820B (zh) | 2013-09-25 |
RU2011148293A (ru) | 2013-06-10 |
EP2099442B1 (en) | 2014-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200905060B (en) | Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy | |
HK1133199A1 (zh) | 組蛋白脫乙酰基酶和微管蛋白脫乙酰基酶抑制劑 | |
HK1220179A1 (zh) | 組蛋白去乙酰的抑制劑 | |
EP1973872A4 (en) | HISTONDEACETYLASE HEMMER AND PROPHARMAKA THEREOF | |
EP1991226A4 (en) | Histone deacetylase INHIBITORS | |
HK1161583A1 (en) | Deacetylase inhibitors and uses thereof | |
EP1735319A4 (en) | Histone deacetylase INHIBITORS | |
EP1755601A4 (en) | HISTONE DEACETYLASE INHIBITORS | |
EP1789381A4 (en) | Histone deacetylase INHIBITORS | |
EP2265590A4 (en) | SELECTIVE INHIBITORS OF HISTONE DEACETYLASE | |
EP2217588A4 (en) | INHIBITORS OF HISTONE DEACETYLASE | |
ZA200906609B (en) | Inhibitors of histone deacetylase | |
IL198263A0 (en) | Hydroxamates as inhibitors of histone deacetylase | |
HK1142597A1 (en) | Inhibitors of histone deacetylase | |
IL193458A0 (en) | Histone deacetylase inhibitors | |
IL214244A (en) | Diastylase Heisone Inhibitors and their use in healing | |
EP1771167A4 (en) | INHIBITORS OF HISTONE DEACETYLASE | |
EP2308868A4 (en) | HISTONDEACETYLASEINHIBITORS AND APPLICATIONS THEREOF | |
HK1136770A1 (en) | Histone deacetylase inhibitors with combined activity on class-i and class- iib histone deacetylases in combination with proteasome inhibitors | |
ZA200808290B (en) | Method of and apparatus for detecting degradation of visual performance | |
EP1784386A4 (en) | HISTONE DEACETYLASE INHIBITORS | |
EP1784194A4 (en) | HISTONE DEACETYLASE INHIBITORS | |
EP1817020A4 (en) | INHIBITORS OF HISTONATE ACETYLASE | |
EP1856276A4 (en) | METHODS OF EVALUATING THE INTEREST OF TREATMENT WITH HISTONE DEACETYLASE INHIBITORS FOR PATIENTS WITH CANCER | |
EP2073812A4 (en) | ACTIVISTS OF HISTONE ACETYLTRANSFERASE AND INHIBITORS OF HISTONE DEACETYLASE IN THE TREATMENT OF ALCOHOLISM |